| Literature DB >> 30662766 |
Aslı Suner1, Brian I Carr2, Hikmet Akkiz3, Oguz Uskudar4, Sedef Kuran4, Yaman Tokat4, Salih Tokmak4, Tugsan Ballı4, Abdulalh Ulku4, Tolga AkCam4, Anıl Delik4, Burcu Arslan4, Figen Doran4, Kendal YalCın5, Nazım Ekinci5, Sezai Yilmaz6, Ayşegul Ozakyol7, Mehmet Yücesoy8, Halil Ibrahim BahCeci9, Kamil Yalcın Polat10, Halis Şimsek11, Necati Ormeci12, Abdulalh Sonsuz13, Mehmet Demir14, Murat KılıC15, Ahmet Uygun16, Ali Demir17, Engin Altıntas18, Gokhan Karakulah19, Tuncer Temel20, Ahmet Bektas21.
Abstract
INTRODUCTION: Several markers of systemic inflammation, including blood C-reactive protein, platelet lymphocyte ratio (PLR) and neutrophil lymphocyte ratio (NLR) have been identified as independent prognosticators for hepatocellular carcinoma (HCC).Entities:
Keywords: C-reactive protein; HCC; NLR; PLR; aggressiveness
Year: 2018 PMID: 30662766 PMCID: PMC6333412 DOI: 10.15761/JTS.1000260
Source DB: PubMed Journal: J Transl Sci
Comparisons of the neutrophils-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR) and the C-reactive protein (CRP) level between HCC patients
| Variable | Group | Values | n | Mean±SD | Median (IQR) | Min-Max | p |
|---|---|---|---|---|---|---|---|
| MTD | <3 | NLR | 65 | 4.33±4.33 | 2.97 (3.82) | 0.37–26.50 | 0.216 |
| ≥3 | 339 | 4.58±4.77 | 3.39 (2.86) | 0.77–46.67 | |||
| <3 | PLR | 63 | 0.11±0.08 | 0.09 (0.08) | 0.03–0.44 | 0.002 | |
| ≥3 | 329 | 0.17±0.14 | 0.13 (0.14) | 0.02–0.96 | |||
| <3 | CRP | 59 | 8.03±15.96 | 2.08 (6.17) | 0.10–81.80 | 0.001 | |
| ≥3 | 284 | 19.19±32.63 | 5.34 (22.18) | 0.10–192.00 | |||
| AFP | <20 | NLR | 163 | 4.09±3.25 | 3.03 (2.96) | 0.37–18.78 | 0.101 |
| ≥20 | 261 | 4.81±5.39 | 3.56 (2.90) | 0.88–46.67 | |||
| <20 | PLR | 160 | 0.15±0.14 | 0.11 (0.11) | 0.02–0.88 | 0.061 | |
| ≥20 | 253 | 0.16±0.13 | 0.13 (0.13) | 0.02–0.96 | |||
| <20 | CRP | 149 | 14.93±34.39 | 3.13 (10.20) | 0.10–192.00 | <0.001 | |
| ≥20 | 215 | 20.97±32.41 | 8.02 (25.64) | 0.10–256.00 | |||
| Multifocality | Unifocal | NLR | 240 | 4.69±4.79 | 3.48 (3.10) | 0.77–46.67 | 0.087 |
| Multifocal | 156 | 4.36±4.66 | 3.15 (3.03) | 0.37–39.29 | |||
| Unifocal | PLR | 230 | 0.16±0.13 | 0.13 (0.13) | 0.02–0.96 | 0.041 | |
| Multifocal | 154 | 0.14±0.13 | 0.10 (0.11) | 0.02–0.88 | |||
| Unifocal | CRP | 200 | 16.85±31.59 | 4.16 (14.95) | 0.10–192.00 | 0.191 | |
| Multifocal | 137 | 18.35±28.91 | 5.46 (25.45) | 0.10–179.00 | |||
| PVT | − | NLR | 283 | 4.68±5.03 | 3.32 (3.05) | 0.37–46.67 | 0.895 |
| + | 135 | 4.21±3.89 | 3.47 (2.83) | 0.68–33.86 | |||
| − | PLR | 275 | 0.15±0.13 | 0.11 (0.11) | 0.02–0.96 | 0.034 | |
| + | 131 | 0.17±0.13 | 0.14 (0.16) | 0.02–0.63 | |||
| − | CRP | 244 | 14.39±28.04 | 3.32 (13.00) | 0.10–180.00 | <0.001 | |
| + | 110 | 28.13±41.83 | 10.70 (29.98) | 0.10–256.00 |
SD, Standard Deviation; IQR, Interquartile Range; Min, Minimum; Max, Maximum;
Wilcoxon rank-sum (Mann-Whitney) test;
p-value<0.05 is significant
Regression models on single variables and final models: (A) Linear regression models of the platelet-to-lymphocyte ratio (PLR) on single variables. (B) Logistic regression models of C-reactive protein (CRP) (≤10/>10) on single variables. (C) Logistic regression models of Glasgow index (<2/=2) on single variables. (D) Logistic regression model of CRP (≤10/>10) on final model. (E) Logistic regression model of Glasgow index (<2/=2) on final model
| Models on single variables | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| (A) | (B) | (C) | ||||||||
| Parameter | β | se(β) | p | 95% C.I. | OR | p | 95% C.I. | OR | p | 95% C.I. |
| MTD (<3/≥3) | 0.052 | 0.018 | 0.004 | 0.017 to 0.088 | 3.144 | 0.002 | 1.529 to 6.463 | 2.957 | 0.007 | 1.347 to 6.491 |
| AFP (<20/≥20) | 0.013 | 0.013 | 0.329 | −0.013 to 0.039 | 2.269 | <0.001 | 1.438 to 3.582 | 2.404 | <0.001 | 1.471 to 3.929 |
| Multifocality (Unifocal/Multifocal) | −0.019 | 0.014 | 0.173 | −0.046 to 0.008 | 1.436 | 0.116 | 0.914 to 2.255 | 1.878 | 0.009 | 1.168 to 3.019 |
| PVT (−/+) | 0.022 | 0.014 | 0.111 | −0.005 to 0.050 | 2.211 | 0.001 | 1.393 to 3.507 | 2.032 | 0.004 | 1.261 to 3.274 |
| Parameter | OR | p | 95% C.I. | OR | p | 95% C.I. | ||||
| MTD (<3/≥3) | 2.860 | 0.007 | 1.328 to 6.160 | 2.674 | 0.024 | 1.142 to 6.261 | ||||
| AFP (<20/≥20) | 1.725 | 0.030 | 1.053 to 2.826 | 1.765 | 0.039 | 1.030 to 3.026 | ||||
| Multifocality (Unifocal/Multifocal) | - | - | - | 1.563 | 0.084 | 0.942 to 2.595 | ||||
| PVT (−/+) | 1.785 | 0.024 | 1.080 to 2.949 | 1.620 | 0.081 | 0.942 to 2.788 | ||||
β: coefficient; se(β): standard error of coefficient; OR, Odds-Ratio; C.I.: confidence interval; AFP, Alpha-fetoprotein; MTD, Maximum Tumor Diameter; PVT, Portal Vein Thrombosis.
All multiple logistic regression final models were executed on all these variables, included together in the model, and selected with backward stepwise method
p-value<0.05 is significant
Final models of logistic regression analysis for (A) Maximum Tumor Diameter (MTD), (B) Alpha-fetoprotein (AFP), (C) Multifocality and (D) Portal Vein Thrombosis (PVT) groups
| (A) | (B) | (C) | (D) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | OR | p | 95% C.I. | OR | p | 95% C.I. | OR | p | 95% C.I. | OR | p | 95% C.I. |
| PLR | 26.338 | 0.046 | 1.056 to 657.005 | - | - | - | - | - | - | - | - | - |
| NLR | - | - | - | - | - | - | - | - | - | 0.947 | 0.094 | 0.888 to 1.009 |
| CRP (>10) | 2.662 | 0.009 | 1.279 to 5.543 | 2.329 | <0.001 | 1.470 to 3.689 | 1.466 | 0.098 | 0.932 to 2.306 | 2.301 | <0.001 | 1.441 to 5.674 |
| PLR | 33.128 | 0.034 | 1.304 to 841.785 | - | - | - | - | - | - | 5.083 | 0.073 | 0.860 to 30.038 |
| NLR | - | - | - | - | - | - | - | - | - | 0.932 | 0.046 | 0.869 to 0.999 |
| Glasgow index (=2) | 2.562 | 0.021 | 1.155 to 5.683 | 2.381 | 0.001 | 1.456 to 3.895 | 1.875 | 0.010 | 1.165 to 3.017 | 1.945 | 0.008 | 1.192 to 3.175 |
OR, Odds-Ratio; C.I.: confidence interval; AFP, Alpha-fetoprotein; MTD, Maximum Tumor Diameter; PVT, Portal Vein Thrombosis.
p-value<0.05 is significant.
All multiple logistic regression final models were executed on all these variables, included together in the model, and selected with backward stepwise method
Results of the area under the receiver operating characteristic (ROC) curve with 95% confidence intervals of PLR, NLR and CRP for Maximum Tumor Diameter (MTD), Alpha-fetoprotein (AFP), Multifocality and Portal Vein Thrombosis (PVT) groups
| Parameter | Area under curve | Standard error | P value | 95% C.I. | |
|---|---|---|---|---|---|
| MTD (<3/≥3) | PLR | 0.607 | 0.038 | 0.010 | 0.533–0.682 |
| NLR | 0.523 | 0.044 | 0.575 | 0.436–0.610 | |
| CRP | 0.642 | 0.038 | 0.001 | 0.566–0.717 | |
| AFP (<20/≥20) | PLR | 0.551 | 0.031 | 0.102 | 0.490–0.611 |
| NLR | 0.544 | 0.031 | 0.155 | 0.483–0.606 | |
| CRP | 0.635 | 0.030 | <0.001 | 0.577–0.694 | |
| Multifocality (unifocal/multifocal) | PLR | 0.555 | 0.032 | 0.088 | 0.492–0.618 |
| NLR | 0.561 | 0.033 | 0.057 | 0.498–0.625 | |
| CRP | 0.456 | 0.032 | 0.168 | 0.393–0.519 | |
| PVT (+/−) | PLR | 0.575 | 0.034 | 0.024 | 0.509–0.641 |
| NLR | 0.498 | 0.032 | 0.960 | 0.435–0.562 | |
| CRP | 0.660 | 0.030 | <0.001 | 0.600–0.719 |
C.I.: confidence interval.
p-value<0.05 is significant
Figure 1Results of the receiver operation characteristic (ROC) curve of PLR, NLR and CRP for (a) Maximum Tumor Diameter (MTD), (b) Alpha-fetoprotein (AFP), (c) Multifocality, and (d) Portal Vein Thrombosis (PVT) groups